TW201120018A - 2,3-dihydrobenzazine compounds for use in therapy - Google Patents

2,3-dihydrobenzazine compounds for use in therapy Download PDF

Info

Publication number
TW201120018A
TW201120018A TW099136761A TW99136761A TW201120018A TW 201120018 A TW201120018 A TW 201120018A TW 099136761 A TW099136761 A TW 099136761A TW 99136761 A TW99136761 A TW 99136761A TW 201120018 A TW201120018 A TW 201120018A
Authority
TW
Taiwan
Prior art keywords
group
dihydro
benzo
cyano
alkyl
Prior art date
Application number
TW099136761A
Other languages
English (en)
Chinese (zh)
Inventor
Jorge Alonso
Lopez Arantxa Encinas
Marcel Muelbaier
Christoph Schultes
Bernd Wendt
Bernd Janssen
Original Assignee
Elara Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elara Pharmaceuticals Gmbh filed Critical Elara Pharmaceuticals Gmbh
Publication of TW201120018A publication Critical patent/TW201120018A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW099136761A 2009-10-27 2010-10-27 2,3-dihydrobenzazine compounds for use in therapy TW201120018A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2009064138 2009-10-27

Publications (1)

Publication Number Publication Date
TW201120018A true TW201120018A (en) 2011-06-16

Family

ID=42044761

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099136761A TW201120018A (en) 2009-10-27 2010-10-27 2,3-dihydrobenzazine compounds for use in therapy

Country Status (3)

Country Link
AR (1) AR078770A1 (fr)
TW (1) TW201120018A (fr)
WO (1) WO2011057892A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958525A (zh) 2011-11-30 2014-07-30 埃科特莱茵药品有限公司 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素
CN103102329B (zh) * 2013-01-24 2015-04-08 华东师范大学 一种2,3-二氢-[1,4]-苯并噻嗪类化合物的合成方法
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
WO2020055164A1 (fr) * 2018-09-12 2020-03-19 크리스탈지노믹스(주) Dérivé de 7-hydroxy-4h-thiéno[3,2-b]pyridin-5-one et son utilisation
CN115557913A (zh) * 2021-07-02 2023-01-03 广东东阳光药业有限公司 苯并氮杂环类化合物及其在药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
PL211057B1 (pl) * 2002-05-13 2012-04-30 Hoffmann La Roche Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny
BR0317572A (pt) 2002-12-20 2005-11-22 Warner Lambert Co Benzoxazinas e seus derivados como inibidores de pi3ks
US20050049309A1 (en) 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
ITMI20042475A1 (it) 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di derivati tiazolidinonici come agenti terapeutici
EP1926485A4 (fr) 2005-08-25 2010-12-15 Univ Emory Inhibiteurs du facteur de transcription hif
RU2407740C2 (ru) 2006-02-13 2010-12-27 Ф.Хоффманн-Ля Рош Аг Гетеробициклические сульфонамидные производные для лечения диабета
WO2007130037A1 (fr) 2006-05-02 2007-11-15 Emory University Inhibiteurs de la hif-1 et leurs procédés d'utilisation
KR100787131B1 (ko) 2006-07-04 2007-12-21 한국생명공학연구원 Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
US7960376B2 (en) 2007-09-14 2011-06-14 Cara Therapeutics, Inc. Benzo-fused heterocycles

Also Published As

Publication number Publication date
WO2011057892A1 (fr) 2011-05-19
AR078770A1 (es) 2011-11-30

Similar Documents

Publication Publication Date Title
TWI359148B (fr)
JP5857168B2 (ja) ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
TWI653226B (zh) 雜環衍生物及其用途
WO2013161919A1 (fr) COMPOSÉ INHIBITEUR DE Trk
HUE033423T2 (en) Pyridine derivatives as rearrangement (RET) kinase inhibitors during transfection
JP2022508751A (ja) Ｐｆｋｆｂ３阻害剤とその使用
KR20150132556A (ko) 과다증식성 장애의 치료를 위한 3-아세틸아미노-1-(페닐-헤테로아릴-아미노카르보닐 또는 페닐-헤테로아릴-카르보닐아미노)벤젠 유도체
TW200918521A (en) Heterocyclic amides and methods of use thereof
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
JP2011502148A (ja) 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
JP2019512474A (ja) シアノ置換インドール化合物およびｌｓｄ１阻害剤としてのその使用
US20120095012A1 (en) Toluidine sulfonamides and their use
KR20170094263A (ko) Ｎａｄｐｈ 옥시다제 억제제인 아미도 티아디아졸 유도체
JP2014509616A (ja) 治療用イミダゾ［１，２−ａ］ピリジン化合物
CN104955826B (zh) 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物
US8822485B2 (en) Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2009335221A1 (en) Toluidine sulfonamides and their use
TW201120018A (en) 2,3-dihydrobenzazine compounds for use in therapy
JP6239149B2 (ja) 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
CA2809778C (fr) Agent therapeutique contre la douleur
EP2914597B1 (fr) Dérivés de pyrazolopyridine en tant que bloquants de ttx-s
WO2012130306A1 (fr) Composés bicycliques de 2,3-dihydrobenzazine destinés à une utilisation thérapeutique
CA3012839A1 (fr) Derives de tetrahydroisoquinoline
TW201127837A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
EP2382190A1 (fr) Toluidine sulfonamides et leur utilisation en tant qu'inhibiteurs